Cargando…
Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection
AIM: To evaluate efficacy/safety of hepatitis C virus (HCV) protease inhibitor boceprevir with pegylated interferon (PEG-IFN) alfa and weight-based ribavirin (RBV) in a phase 3 trial. METHODS: A prospective, multicenter, phase 3, open-label, single-arm study of PEG-IFN alfa, weight-based RBV, and bo...
Autores principales: | Sherman, Kenneth E, Kang, Minhee, Sterling, Richard, Umbleja, Triin, Marks, Kristen, Kiser, Jennifer J, Alston-Smith, Beverly, Greaves, Wayne, Butt, Adeel A, the ACTG 5294 BIRTH Study Team |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295161/ https://www.ncbi.nlm.nih.gov/pubmed/28217259 http://dx.doi.org/10.4254/wjh.v9.i4.217 |
Ejemplares similares
-
Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients
por: Bedimo, Roger, et al.
Publicado: (2016) -
Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection
por: Erqou, Sebhat, et al.
Publicado: (2014) -
The Effect of Hepatitis C Virologic Clearance on Cardiovascular Disease Biomarkers in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
por: Chew, Kara W., et al.
Publicado: (2014) -
Miliary Tuberculosis Coinfection with Human Immunodeficiency Virus
por: Esteve, Erika, et al.
Publicado: (2010) -
Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
por: Lo Re, Vincent, et al.
Publicado: (2015)